Corona Viruses: A Review on SARS, MERS and COVID-19

Nihala Naseefa Chathappady House, Sheeba Palace and Honey Sebastian
Vimala College (Autonomous), Thrissur, KL, India.

ABSTRACT: After the outbreak of SARS and MERS, the world is now in the grip of another viral disease named COVID-19 caused by a beta Coronavirus – SARS COV-2 which appears to be the only one with a pandemic potential. The case of COVID-19 was reported in the Hubei province of Wuhan city in Central China at the end of December 2019 and it is suspected that the sea food market played a role in this outbreak which was closed abruptly. Subsequently, a Public Health Emergency of International Concern was declared on 30 January 2020 by the World Health Organization. Both SARS and MERS corona viruses had its reservoir in bats and were transferred to humans from palm civets and camels respectively. This virus can be transmitted through airborne droplets. Natural reservoir and intermediate host of COVID-19 is yet to be identified. This paper reviews the occurrences of viral diseases in the recent times including SARS and MERS. As an addition to this, the paper will contain a detailed examination of the COVID-19 Pandemic.

KEYWORDS: SARS-COV, MERS-COV, COVID-19, Coronavirus

Introduction

A virus is a small parasite that cannot undergo self-reproduction and once it infects a susceptible cell, the virus can direct the cell machinery to produce more viruses.1 The Coronaviridae family comprising the genera Corona Virus and Torovirus has been classified as members of the Order Nidovirales.2,3 They mutate and also recombine frequently. Laboratory diagnosis is best accomplished by finding viral RNA through polymerase chain reaction. These are enveloped viruses with club-like spikes projecting from their surface.4 Coronaviruses (COVs) commonly bring about mild but occasionally more severe community-acquired acute respiratory infections in humans. They also affect multifarious animals and several have even crossed the barrier, producing outbreaks of severe human respiratory disease. As of 10th March, 2019, 2374 laboratory cases were confirmed. The earliest isolation of this virus was from the Wuhan sea food market in China in the first week of January 2020.5

Community acquired Coronavirus infections cause about 15% of common cold. They are typically epidemic in the winter. There are no accepted effective antiviral drugs. Prevention is done through epidemiologic methods and the use of appropriate respiratory precautions in hospital settings. The SARS epidemic and MERS outbreaks were controlled through careful case identification, quarantine and by the use of barrier precautions. WHO advised staying away from public places and avoiding close contact with infected persons and animals in order to prevent the rapid spread of the disease.6

Dromedary camels in Saudi Arabia encamp for 3 different HCOV species including the MERS HCOv.7 The spread of MERS-COV from dromedary camels, the high case-fatality rates, emphasize the need for preventive and therapeutic measures.8

The structure of this virus holds a helical nucleocapsid with 30 kb, plus-sense RNA genome coiled within an envelope that contains the S, M and E glycoproteins. Some coronaviruses have an additional membrane glycoprotein HE in them.

The name Corona viruses (COVs) was derived from the Greek word meaning Crown referring to the crown or corona like appearance of COV viruses when observed under an electron microscope.10 The Coronaviridae and Arteriviridae are viruses with monopartite plus-stranded RNA genomes that replicate using a nested (nido) set of overlapping sub genomic mRNAs.11 The spikes of coronaviruses, typically described as club-like or petal-shaped, emerge from the virion surface as stalks with bulb-like distal termini. Some of the variation in particle size and shape was likely attributable to stresses exerted by virion purification or distortions introduced by negative staining of samples for electron microscopy. Through sequencing and antigenicity, the pioneer divisions of the animal and human coronaviruses discovered were as follows: group 1, containing HCOV-229E; group 2, enclosing HCOV-OC43; group 3, including the infectious bronchitis virus. The family Coronaviridae, is divided into 4 genera alpha-, beta-, gamma- and deltacoronavirus (α-, β-, γ- and δ-COV).12

During the winter of 2002 to 2003, there was an outbreak of a new disease, severe acute respiratory syndrome (SARS), where the intermediate hosts, were probably the Palm civet (Paguma larvata) and the Raccoon dog (Nyctereutes procyonoides).13,14

The last known case of the SARS epidemic occurred in mid-2004. More recently there was an outbreak of a related but different COV, the Middle East respiratory syndrome coronavirus (MERS-COV).15 A total of 2374 individuals were infected – a majority with acute respiratory symptoms – that were arduous in most and fatal in 823 (as of 10th March,
The dromedary camels are the reservoir of MERS CoV, although evidence suggests that bats may be infected with related viruses.18

Betacoronavirus genus consists of 4 lineages: A, B, C and D.19,20 Alpha and Beta coronavirus descend from the bat gene pool.21-23 The group 2 coronavirus has a smaller protein called hemagglutinin esterase (HE) which is functionally similar to S protein.24 In humans, CoV infections include mild diseases, such as the common cold, to more severe manifestations, like bronchitis and pneumonia with renal involvements.25 The first human coronavirus (HCoV) was isolated from the nasal discharge of patients with common cold.26 Currently, 6 different CoV strains are known to infect humans.27

229E and OC43 are the 2 main HCoVs (from lineage Alpha and Beta) that cause 15% to 29% of all common colds.28 SARS-CoV caused the outbreak of severe respiratory disease in China during 2002 to 200329 and MERS-CoV is responsible for an ongoing outbreak of severe respiratory disease in the Middle East since 2012.30 The epidemiology and pathogenesis of HCoVs are discussed in the following sections and are summarized in Table 1.

In general, 229E, OC43 and NL63 are distributed globally, transmitted predominantly during the winter season in temperate countries,31 while NL63 showed a spring–summer peak of activity.32 Today n-CoVs are recognized as one of the most rapidly evolving viruses moving to its higher genome nucleotide substitution rates and recombination.33 The distribution of n-CoVs varies according to its geographical area and season.34 Although the corona virus was identified 60 years ago, they received attention at the time of the SARS outbreak.

Severe Acute Respiratory Syndrome (SARS)
SARS is a viral disease associated with an outbreak of a typical pneumonia in Guangdong Province, China. A newly identified group of coronavirus, the SARS Coronavirus, was the causative agent of this life threatening pneumonia in humans.35-39 Typical clinical presentations of SARS are viral pneumonia with rapid respiratory deterioration, fever, chills, myalgia, malaria and non-productive cough being the major presentations showing symptoms, whereas sore throats are less frequently seen one, with an incubation period of 2 to 7 days.40,41 SARS like viruses were isolated from a few Himalayan palm civets (Paguma larvata) and the Raccoon dog (Nyctereutes procyonoides) at Shenzhen sea food market.42,43

It has been discovered that humans were introduced to this epidemic with the spread of a closely related bat virus among palm civets or other animals that were for sale in the live wild game markets and then to humans. The virus then adopted itself through wild action and recombined until it transmitted readily among humans. RT-PCR method was adopted for the diagnosis of this viral disease.44 Ribavirin Drug: Interferon and Lopinavir/ritonavir are the antiviral agents used in the therapy of SARS. Ribavirin is a ribonucleoside analogue that prevents the replication of a large number of RNA and DNA Viruses.45,46

| COUNTRY     | TOTAL CASES | TOTAL DEATHS |
|-------------|-------------|--------------|
| USA         | 7637066     | 214615       |
| India       | 6626291     | 102746       |
| Brazil      | 4915289     | 146375       |
| Russia      | 1225889     | 21475        |
| Colombia    | 855052      | 26712        |
| Peru        | 828169      | 32742        |
| Spain       | 810807      | 32086        |
| Argentina   | 798486      | 21018        |
| Mexico      | 761665      | 79088        |
| South Africa| 681289      | 16976        |
| France      | 619190      | 32230        |
| UK          | 502978      | 42350        |
| Iran        | 471772      | 26957        |
| Chile       | 470179      | 12979        |
| Iraq        | 379141      | 9399         |
| Bangladesh  | 370132      | 5375         |
| Saudi Arabia| 336389      | 4875         |
| Italy       | 325329      | 35986        |
| Philippines | 324762      | 5840         |
| Turkey      | 324443      | 8441         |
| Pakistan    | 315260      | 6517         |
| Indonesia   | 307120      | 11253        |
| Germany     | 301571      | 9602         |
| Israel      | 268175      | 1719         |
| Ukraine     | 230236      | 4430         |
| Canada      | 166156      | 9481         |
| Ecuador     | 141034      | 11647        |
| Romania     | 137491      | 5048         |
| Bolivia     | 136868      | 8101         |
| Netherlands | 135892      | 6454         |
| Belgium     | 130235      | 10064        |
| Poland      | 102080      | 2659         |
| Oman        | 101814      | 985          |
| UAE         | 99733       | 429          |
| China       | 85470       | 4634         |
| Australia   | 27149       | 894          |
| S. Korea    | 24164       | 422          |
| Croatia     | 17797       | 300          |
| Srilanka    | 34714       | 13           |

Table 1. CoV-2019 cases reported (as per the information collected on 18-05-2020).
Even though improvements were seen in some patients, some other reports failed to identify this; there were numerous adverse effects associated with ribavirin or other therapies, particularly the transaminase elevation. IFN are a multigene family of inducible cytokines, possessing antiviral activity with Interferon β being far more effective against SARS. Lopinavir and Ribavirin are combined and used for the treatment of human immunodeficiency virus (HIV) and have limited side effects.

**Middle East Respiratory Syndrome (MERS)**
The first case was identified in a patient with acute pneumonia and renal failure in Jeddah, Kingdom of Saudi Arabia (KSA) in June 2012. Sequencing was done at the Erasmus Medical Centre (EMC) in Rotterdam, the Netherlands, where the virus was named ‘Human Coronavirus EMC (HCOVEMC)’ and further, renamed by the International Committee on Taxonomy of Virus as the Middle East Respiratory Syndrome Coronavirus (MERS COV). The virus was propagated through African green monkeys and rhesus macaque kidney cells. The incubation period is 2 to 14 days [medium of approximately 5.5 to 6.5 days]. Clinical symptoms include fever, cough, sore throat, shortness of breath, myalgia, chest pain, malaise and gastrointestinal symptoms, such as diarrhea, vomiting and abdominal pain. A large proportion of severely ill patients required mechanical ventilation. Interestingly, many of the reported secondary cases showed mild respiratory symptoms or were even asymptomatic.

Chest radiographs of a large percentage of patients admitted to the hospital showed airspace and interstitial opacities, with subtle to extensive, unilateral to bilateral and focal to diffuse distribution; Moreover, the air space opacities vary in their distribution, as reticular or reticulonodular, and demonstrate thickening of broncho-vascular areas. Gastrointestinal symptoms such as diarrhea and vomiting are sometimes seen in patients. The virus acquired by the dromedary camels subsequently spread to other animals in the Middle East region. No effective antiviral drug against MERS has been discovered, which is another factor contributing to the huge death rate.

Various IFN regimens in combination with nitro viruses have been intermittently administered to severely ill patients, although typically in an ad hoc manner and in the absence of systematic evolution.

**COVID-19**
On 31 December 2019, the WHO China Country Office was informed about a pneumonia of unknown cause in Wuhan City, Hubei Province—China. As of 3 January 2020, a total of 44 patients with pneumonia had been reported to the WHO by the national authorities in China. The cluster was initially reported when the Chinese authorities identified a new coronavirus (COV) as the causative agent of SARS-CoV2 which was named as COVID-19 by the World Health Organization, which is an acronym of ‘coronavirus disease 2019’.

SARS-CoV2, designated by The International Committee on Taxonomy of Viruses (ICTV) on 11 February 2020 is the most recent human pneumonia virus with high outbreak potential. Cases were reported in other cities, leading to a global outbreak. The first SARS related Corona virus was discovered in the horseshoe bat species (Rhinolophus sinicus). Moreover, they belong to a large family of single-stranded RNA viruses (+ssRNA) that are isolated from different animal species. There are speculations, about their animal origin. Available evidence suggests that the outbreak was associated with exposures to the seafood market and hence, concerns markets in Wuhan were closed on first January 2020 for environmental sanitation and disinfection. In March 2019, this outbreak was characterized as a pandemic by the WHO. This is the first pandemic known to be caused by a new coronavirus; the third zoonotic human coronavirus (COV) of the century has features typical of the coronavirus family and was placed in the beta coronavirus 2b lineage. COVID-19 was declared as the sixth Public Health Emergency of International Concern by the WHO, following H1N1 (2009), polio (2014), Ebola in West Africa (2014) ZIka (2016) and Ebola in the Democratic Republic of Congo (2019). The incubation period is the same to other known human coronaviruses, including SARS and MERS. 2019 n-COV is the seventh member of the family of coronaviruses that are infectious to humans.

The Common symptoms are fever, cough, myalgia sputum production, headache, haemoptysis and diarrhea. In the early stages, respiratory infections in patients developed to Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure and other serious complications. This disease might badly affect older patients with comorbidities and ARDS. Based on some studies conducted in Hong Kong, in and around Wuhan as well as Shenzhen has revealed that group O, people had more resistivity towards SARS-CoV-2, because of the ABO antibodies. In fact, those with blood group A had much more risk of being affected by this virus. The vital signs were stable in most cases while leukopenia and lymphopenia were common. Mortality has been found to be remarkably higher in patients with increased TrT (Troponium T) level. The further elevation of IP-10, MCP-3 and IL-1ra, shows the severity and the fatal outcome of this viral disease.

Phylogenetic analysis of viral genome uncovered the relatedness of the virus to SARS like coronavirus, genus beta corona virus, sub genus Sarbeco virus that had previously been found in bats. Moreover, phylogenetic analysis of coronavirus of different Species indicated that 2019 n-COV might have originated from bats. The viral sequence shows 79.6% identity to SARS-CoV and 96% identical at the whole genome level to a bat coronavirus. Moreover, they are closely related to a bat derived corona virus – bat SL COV ZC44, bat SL COV ZXC2.

The virus which causes COVID-19 most probably has its ecological reservoir in bats. Since there is a very limited close
contact between humans and bats, transmission of virus to humans might have occurred through an intermediate animal host like a domestic animal, a wild animal or a domesticated wild animal which has not yet been identified. Asymptomatic patients can still infect the other which means that COVID-19 is transmittable even during the incubation period. The nosocomial transmission of COVID-19, facilitated by the mobile phones of health care workers and hospital equipment, cause severe problems and further accelerate the rate of transmission of this already hiking viral disease. The vertical transmission of COVID-19; put pregnant women and fetuses at a higher risk of being infected by the virus. This is primarily due to the high expression of ACE2 receptors in the human maternal interphase. Transmission through organ transplantation and surgical operation; as the Corona viruses home in the respiratory tract and its secretions. These pose a risk to health care providers if the patients require surgery.

SARS COV-2, can remain for hours on different surfaces and was more stable and last longer on plastic as well as stainless steel which were comparatively low in copper and cardboard surfaces. The basic reproductive number (R0), has been used as a parameter to calculate the infectivity index. In MERS and SARS epidemic, the value was found be approximately 2, which in turn indicate that each infected person could infect 2 others in an effective contact. But for COVID-19 this index value was slightly higher. The data calculated from Wuhan was 2.2, further studies on this have received different values (1.95–6.47).

Ensuring early diagnosis and appropriate quarantine measures are the key factors to check the rate of transmission of the virus considerably. The current method for the diagnosis of COVID-19 includes detection of the virus by genomic techniques like polymerase chain reaction (PCR) – or deep sequencing which relies on the presence of the viral genomes in sufficient amounts. This method often fails to detect the viral infection, if collection procedure is not optimal or if the patient has low viral load, typically, during the early stage of the disease or if it is suppressed by host immunity. If the sample is obtained at a later stage, a supplementary 18 m test can provide a better sensitivity mean of PCR based method alone.

However, new sensitive PCR essays can even further improve the detection method when combined with IgM ELISA arrays. The 2 diagnostic tests for emergency use are the Genesig real time PCR coronavirus, an open system more suitable for laboratories with moderate sample testing capacity and the cobas(R) SARS cov-2, core for use in the Cobas (R) 6800/8500 system is a closed system array for larger laboratories. Common laboratory findings include lymphopenia and bilateral ground glass opacity. At present there are no vaccines or antiviral treatments for animal coronavirus. It is observed that in more than 20% of patients, the viral RNA remained positive in feces even though it turned negative in the respiratory tract. This shows that the viral gastro intestinal infection and potential fecal, oral transmission can last even after the viral clearance in the respiratory tract of the infected person. Hence the rRT-PCR testing from feces is also an important process to be carried out in the COVID-19 treatment plan.

However various research efforts are under way and number of vaccine candidates are under work which includes inactivated vaccine, adenoviral vector vaccine, recombinant subunits vaccine etc. The S protein, remains as the main factor for the vaccine development. The Cryo-EM structure of SARS COV-2 S Trimer has also accelerated the vaccine development process.

Patients admitted to ICUs had a high concentration of cytokines in plasma which shows that the cytokine storm is associated with the severity of this disease. In a group of patients by the end of the first week, there is a chance for the progression of the disease to pneumonia, respiratory failure and death. This step up is due to the increased inflammatory cytokines (IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A and TNFs). The GM-CSF, IL-6 CD4T cells isolated from such patients were typically high compared to the non-ICU patients. This holds that the inhibition of excessive inflammatory response might act as an adjacent therapy for COVID-19. In most cases, it takes repeated attempts to accurately spot the presence of viral RNA from the deep oral swab samples, hence analysis of deep airway samples [like sputum, bronchoalveolar lavage, tracheal secretions] or stool, would be more effective in determining the viral presence than the prior one. No therapeutics and pharmaceutical products have yet been shown to be safe and effective. Lopinavir and Ritonavir are licensed treatment for n-COV, evidence for COVID-19, MERS and SARS has yet to show whether it can improve clinical outcomes or prevent infection. Interferon beta 1a is used to treat multiple sclerosis. Chloroquine and hydroxychloroquine are very closely related and used to treat malaria and rheumatology conditions respectively. Nucleoside analysis such as ribavirin may be potentially beneficial for the treatment of COVID-19. Ribavirin is approved for treating respiratory syncytial virus (RSV) infection and used extensively during SARS and MERS outbreak. Ribavirin has been recognized as a promising antiviral drug against RNA virus infections in cultured cells in mice and non-human primates (NHP) models.

The new antiviral drug ribavirin as well as chloroquine at cc50 of 1 mm is found to be effective in preventing replication of this Virus. Chloroquine and hydroxychloroquine are 2 of the most fascinating drugs developed in the last 60 years. Studies have suggested that chloroquine, an immunomodulant drug traditionally used to treat malaria, is effective in reducing viral replications and other infections. COVID-19 pandemic has spread very quickly taking only 30 days to expand from Hubei province to the rest of the mainland; however rapid rate of increase in illness among people and evidence of human to human transmission suggest that 2019 n-COV is more infectious, spreading with a staggering speed. Immunomodulators like Baricitinib, eculizumab, interferons; multisystem cell therapy, autologous adipose derived mesenchymal stem cell therapy, corticosteroids, teicoplanin, ivermectin, convalescent plasma therapy, were administered on patients with COVID-19.
Teicoplanin is a glycopeptide antibiotic used to treat bacterial infections caused by staphylococcus aureus and streptococcus, which has been adopted to treat COVID-19. Moreover, it is identified that teicoplanin could inhibit the entry of HIV-1-2019-NCoV-S pseudoviruses with the IC50 value of 1.66 µm. They even prevent the S protein activation by directly inhibiting the enzymatic activity of cathepsin L. They are often recommended in the early stage of this viral disease. It seems that the aptamer molecules might be effective in treating the corona virus to some extent. They could be an effective anti-viral treatment could tackle the disease to some extent. Moreover, wearing of mask and eye protection could lead to timely treatment and prevent the spread of COVID-19.

Natural products and their derivatives have potential to treat the viral infections. Treatment carried out using Chinese, Indian as well as Iranian herbal medicine solely and in combination with western medicines had a positive impact, though their clinical trials remained to be known. Herbal traditional medicines have been used in china since the very beginning of SARS-CoV-2. Some of this have even prevented the infections of a healthy person and thereby has contributed towards the improvement in health status of patients with mild or severe symptoms. Some of the herbal agents that might be helpful in treatment of COVID-19 include, Echinacea purpurea, Curcumin, Cinchona SP, Xanthorrhizol etc.

Preventive measures have been discussed to reduce the transmission and to tackle this viral disease. Social distancing is imperative to run down the number of cases. Furthermore, individuals’ abidance to prescriptions and reduction of social activity should be applied on all social groups for an effective result. Moreover, wearing of mask and eye protection could tackle the disease to some extent.

REFERENCES

1. Lodish H, Berk A, Lawrence Zipursky S, et al. Molecular Cell Biology. 4th ed. W. H. Freeman and Co; 2000.
2. Peiris JSM. Corona Viruses. In: Douglas D, Richman Whitley RJ, Hayden FG eds. Clinical Virology. 4th ed. ASM Press; 2012.
3. Gonzalez JM, Gomez-Puertas P, Cavanagh D, Gorbalenya AE, Enjuanes L. A comparative sequence analysis to revise the current taxonomy of the family Coronavirus. Arch Virol. 2003;148:2207-2235.
4. Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
5. Hunter RH, Sykes K, Lowman SG, Duncan R, Satiriano WA, Belza B. Environmental and policy change to support healthy aging. J Aging So Policy. 2011;23(4):354–371.
6. Kumar D, Malviya R, Kumar Sharma P. Corona virus: a review of COVID-19. EJMO 2020;4:8-25.
7. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.
8. Bahaaraon S, Ziad A, Memish. MERS-CoV as an emerging respiratory illness: a review of prevention methods. Travel Med Infect Dis. 2019;32:101520.
9. Muhammad Adnan Shereen Sultan Khan Abeer KazmiNadia BashirRabeea Siddique. A Covid-19 infection: origin, transmission and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.
10. Woo PSC, Huang Y, Lau SKP, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;12:1804–1820.
11. Kathryn v holmes. Coronaviruses (Coronaviridae). In: Granoff A, Webster RG.eds. Encyclopedia of Virology. Elsevier; 1999:291–298.
12. Huilow BJG, Dr. Haan CAM, Bovis BJ. Coronavirus. In: Ziebuhr J ed. Advances in Virus Research. vol. 96. Academic Press; 2016:2–295.
13. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
14. Ge XY, Li J-J, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538.

Figure 1.

Structure of respiratory syndrome causing human coronavirus.

Conclusion

The spread of the novel coronavirus is declared as a pandemic by the World Health Organization (WHO). The spread of this disease is possible even during the incubation period from an asymptomatic person and this entirely poses a serious threat which can result in the death of thousands. The investigation to find the natural reservoir, intermediate host and vaccines are in progress. Further, there are many unanswered questions with regard to COVID-19 — like the root cause of outbreak, medium of transmission, effective treatment, prevention method, duration of transmission etc. MERS and SARS coronaviruses have shown that these viruses are able to cross the species barrier. In view of the new virological studies, coronaviruses are pathogens infecting a wide range of mammals that are often in contact with humans, thus providing the basis for future zoonotic outbreaks.
15. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820.
16. Assiri A, McGeer A, Peiris JM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407-416.
17. Olobo IK, Tomczyk SM, Al-Atiama AM, et al. MERS-CoV outbreak in Jeddah—a link to health care facilities. N Engl J Med. 2015;372:846-854.
18. Sabir JS, Lam TTY, Ahmed MMM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science. 2016;353:81-84.
19. "Phylogeny of SARS-like betacoronaviruses.“ Cryptovirus. Retrieved 18 January 2020.
20. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Familial clusters of MERS-CoV infection in Saudi Arabia. J Infect Dis. 2013:368:2487–2494.
21. Woo PC, Wang M, Lau SK, et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol. 2007;81:1574-1585.
22. Lau SK, Woo PC, Yip CC, et al. Isolation and characterization of a novel Beta-coronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits. J Virol. 2012;86:5481-5496.
23. Lau SK, Poon RW, Wong BH, et al. Coexistence of different genotypes in the same bat and serological characterization of Rousettus bat coronavirus HKU9 belonging to a novel Betacoronavirus subgroup. J Virol. 2010;84:11385-11394.
24. Langeresi MA, Van Vliet AL, Boot W, De Groot RJ. Attachment of mouse hepatitis virus strain A59 to the hexameric hemagglutinin-esterase and not by the spike protein. J Virol. 2010;84:8970-8974.
25. Wevers BA, van der Hoek L. Recently discovered human coronaviruses. Clin Lab Med. 2009;29:715-724.
26. Tyrrell DA, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. Nature. 1965;195:1467-1470.
27. Kin N. Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombining genotypes. Virus. 2015;7:2338-2377.
28. Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med. 1974;47:234-251.
29. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome with human β-interferon-γ. N Engl J Med. 2003;349:1775-1780.
30. Vincent CCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome (SARS): an overview. Infection. 2003;31:165-170.
31. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809.
32. Samuel CE. Anti-viral actions of interferons.was also been used for the treatment of SARS. Clin Microbiol Rev 2001;14(4):778-809.
33. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. J Virol. 2009;83:11151-11160.
34. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of SARS-CoV and MERS-CoV by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176:6085-6092.
35. Emery SL, Erdman DD, Bowen MD, et al. Real time reverse transcription polymerase chain reaction assay for SARS associated coronavirus. Emerg Infect Dis. 2004;10(2):311-316.
36. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus – associated SARS Pneumonia: a prospective study. Lancet 2003;361:1767-1772.
37. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995-2005.
38. Booth CM, Marakis IM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809.
141. Sharun K, Dhama K, Kumar Patel S, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob* 2020;19:23.

142. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787.

143. Banerjee K, Nandy M, Dalai CK, Newaz Ahmed S. The battle against COVID 19 pandemic: what we need to know before we “test fire” ivermectin. *Drug Res.* 2020;70(8):337-340.

144. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. *New Microbes New Infect* 2020;22:100684.

145. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. *Antimicrob Agents Chemother* 2020;64:e00483-20.

146. Chen Z, Wu Q, Chen J, Ni X, Dai J. A DNA aptamer based method for detection of SARS-CoV-2 nucleocapsid protein. *Trends in Biotechnology* 2020;35(3):351-354.

147. Torabi R, Ranjbar R, Halaji Md, Heiat M. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: a systematic review. *Mol Cell Probes* 2020;53:101636.

148. Mao K, Zhang H, Yang Z. Can a paper-based device trace COVID-19 sources with wastewater-based epidemiology? *Environ Sci Technol* 2020;54:3733-3735.

149. Kitajima M, Ahmed W, Bibby K, et al. SARS-CoV-2 in wastewater: State of the knowledge and research needs. *Sci Total Environ.* 2020;739:139076.

150. Mirzaie A, Halaji M, Dehkordi SF, Ranjbar R, Noorbazargan H. A narrative literature review on traditional medicine options for treatment of coronavirus disease 2019 (COVID-19). *Complement Ther Clin Pract.* 2020;40:101214.

151. Benarba B, Pandiella A. Medicinal plants as sources of active molecules against COVID-19. *Front Pharmacol.* 2020;11:1189.

152. Nugraha RV, Ridwanuyah H, Ghozali M, Khairani AF, Atik N. Traditional herbal medicine candidates as complementary treatments for COVID-19: a review of their mechanisms, pros and cons. *Evi Based Complement Alternat Med* 2020;2020:2560645.

153. Basile C, Combe C, Pizzarelli F, et al. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. *Nephrol Dial Transplant* 2020;35:737-741.

154. Adhikari SP, Meng S, Wu Y-J, et al. Epidemiology, causes, clinical manifestations and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infect Dis Poverty.* 2020;9:29.

155. Wu Z, McGooog J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China summary of a report of 72 314 cases from the Chinese center for disease control and prevention. *JAMA* 2020;323:1239-1242.

156. WHO: coronavirus disease (COVID 19) advice for the public.

157. Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong social distancing measures in the United States reduced the COVID-19 growth rate. *Health Aff (Millwood)* 2020;39(7):1237-1246.

158. Muscillo A, Pin P, Razzolini T. Covid19: Unless one gets everyone to act, policies may be ineffective or even backfire. *PLoS One* 2020;15:e0237057.

159. De Van J. The effect of COVID-19 and subsequent social distancing on travel behavior. *Interdisciplinary Perspect.* 2020;5:100121.